Kisunla™ (donanemab-azbt), pronounced kih-SUHN-lah, is used to treat adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of ...

In particular, semiconductor specialist Nvidia is viewed as the engine powering the AI vehicle right now. Demand for its most ...

Indianapolis: Eli Lilly and Company's has announced that the Ministry of Health, Labour and Welfare Japan has approved Kisunla (donanemab-azbt, 350 mg/20 mL every four weeks injection for ...

Eli Lilly has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for Kisunla (donanemab-azbt) ...

Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai ...

Roche narrows pipeline to focus more on weight-loss franchise, following setbacks in Alzheimer's and lung cancer ...

Eli Lilly’s Alzheimer’s drug, Kisunla, has received approval from the Japanese Ministry of Health, Labour and Welfare. This ...

Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...

This briefing covers notable health news: the US is donating 1 million mpox vaccine doses to Africa, AstraZeneca’s breast ...

Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive ...

(RTTNews) - Eli Lilly and Company (LLY) Tuesday said its Kisunla for the treatment of adults with early symptomatic Alzheimer's disease has been approved by the Ministry of Health, Labour and Welfare ...

Sen. Bernie Sanders argues that Novo Nordisk charges Americans substantially higher prices for its drugs than it does for ...